PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach
Objective: To evaluate the safety and tolerability of epigallocatechin gallate (EGCG) in high doses and its efficacy to slow down disease progression in patients with…Nilotinib for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of nilotinib on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Effects of mannitol treatment in a mice model of multiple system atrophy (MSA)
Objective: The aim of this study was to examine the effect of mannitol treatment in a mice model of MSA. Background: Alpha-synuclein aggregation represents the…Rapamycin for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Patient Perspective in Multiple System Atrophy
Objective: To report patient and/ or caregiver perspective in Multiple System Atrophy (MSA). Background: The majority of literature on MSA’s natural history comes from single…Is safinamide useful for atypical Parkinsonian syndromes?
Objective: Seeking new treatment strategies in atypical Parkinsonian syndromes Background: Atypical parkinsonian syndromes (APS) include several entities leading to parkinsonism with atypical features such as…The role of deep brain stimulation targeting GPi in patients with multiple system atrophy
Objective: To report clinical outcomes of two patients diagnosed with MSA-P who underwent bilateral deep brain stimulation (DBS). Background: The role of DBS in patients…Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial
Objective: To explore intrathecal administration of autologous mesenchymal stem cells (MSCs) as therapeutic approach to multiple system atrophy (MSA). Background: MSA is a rapidly progressive…Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations
Objective: To present the detailed clinical features of a patient with familial MSA carrying compound heterozygous COQ2 mutations and report the outcome of a high-dose ubiquinol…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »